Hereditary combined deficiency of the vitamin K-dependent clotting factors

<p>Abstract</p> <p>Hereditary combined vitamin K-dependent clotting factors deficiency (VKCFD) is a rare congenital bleeding disorder resulting from variably decreased levels of coagulation factors II, VII, IX and X as well as natural anticoagulants protein C, protein S and protein...

Full description

Bibliographic Details
Main Authors: Mariani Guglielmo, Napolitano Mariasanta, Lapecorella Mario
Format: Article
Language:English
Published: BMC 2010-07-01
Series:Orphanet Journal of Rare Diseases
Online Access:http://www.ojrd.com/content/5/1/21
id doaj-eaf329b6c4f0400db0a65f490ab4f878
record_format Article
spelling doaj-eaf329b6c4f0400db0a65f490ab4f8782020-11-25T00:32:14ZengBMCOrphanet Journal of Rare Diseases1750-11722010-07-01512110.1186/1750-1172-5-21Hereditary combined deficiency of the vitamin K-dependent clotting factorsMariani GuglielmoNapolitano MariasantaLapecorella Mario<p>Abstract</p> <p>Hereditary combined vitamin K-dependent clotting factors deficiency (VKCFD) is a rare congenital bleeding disorder resulting from variably decreased levels of coagulation factors II, VII, IX and X as well as natural anticoagulants protein C, protein S and protein Z. The spectrum of bleeding symptoms ranges from mild to severe with onset in the neonatal period in severe cases. The bleeding symptoms are often life-threatening, occur both spontaneously and in a surgical setting, and usually involve the skin and mucosae. A range of non-haemostatic symptoms are often present, including developmental and skeletal anomalies. VKCFD is an autosomal recessive disorder caused by mutations in the genes of either <it>gamma-glutamyl carboxylase </it>or <it>vitamin K2,3-epoxide reductase complex</it>. These two proteins are necessary for gamma-carboxylation, a post-synthetic modification that allows coagulation proteins to display their proper function. The developmental and skeletal anomalies seen in VKCFD are the result of defective gamma-carboxylation of a number of non-haemostatic proteins. Diagnostic differentiation from other conditions, both congenital and acquired, is mandatory and genotype analysis is needed to confirm the defect. Vitamin K administration is the mainstay of therapy in VKCFD, with plasma supplementation during surgery or severe bleeding episodes. In addition, prothrombin complex concentrates and combination therapy with recombinant activated FVII and vitamin K supplementation may constitute alternative treatment options. The overall prognosis is good and with the availability of several effective therapeutic options, VKCFD has only a small impact on the quality of life of affected patients.</p> http://www.ojrd.com/content/5/1/21
collection DOAJ
language English
format Article
sources DOAJ
author Mariani Guglielmo
Napolitano Mariasanta
Lapecorella Mario
spellingShingle Mariani Guglielmo
Napolitano Mariasanta
Lapecorella Mario
Hereditary combined deficiency of the vitamin K-dependent clotting factors
Orphanet Journal of Rare Diseases
author_facet Mariani Guglielmo
Napolitano Mariasanta
Lapecorella Mario
author_sort Mariani Guglielmo
title Hereditary combined deficiency of the vitamin K-dependent clotting factors
title_short Hereditary combined deficiency of the vitamin K-dependent clotting factors
title_full Hereditary combined deficiency of the vitamin K-dependent clotting factors
title_fullStr Hereditary combined deficiency of the vitamin K-dependent clotting factors
title_full_unstemmed Hereditary combined deficiency of the vitamin K-dependent clotting factors
title_sort hereditary combined deficiency of the vitamin k-dependent clotting factors
publisher BMC
series Orphanet Journal of Rare Diseases
issn 1750-1172
publishDate 2010-07-01
description <p>Abstract</p> <p>Hereditary combined vitamin K-dependent clotting factors deficiency (VKCFD) is a rare congenital bleeding disorder resulting from variably decreased levels of coagulation factors II, VII, IX and X as well as natural anticoagulants protein C, protein S and protein Z. The spectrum of bleeding symptoms ranges from mild to severe with onset in the neonatal period in severe cases. The bleeding symptoms are often life-threatening, occur both spontaneously and in a surgical setting, and usually involve the skin and mucosae. A range of non-haemostatic symptoms are often present, including developmental and skeletal anomalies. VKCFD is an autosomal recessive disorder caused by mutations in the genes of either <it>gamma-glutamyl carboxylase </it>or <it>vitamin K2,3-epoxide reductase complex</it>. These two proteins are necessary for gamma-carboxylation, a post-synthetic modification that allows coagulation proteins to display their proper function. The developmental and skeletal anomalies seen in VKCFD are the result of defective gamma-carboxylation of a number of non-haemostatic proteins. Diagnostic differentiation from other conditions, both congenital and acquired, is mandatory and genotype analysis is needed to confirm the defect. Vitamin K administration is the mainstay of therapy in VKCFD, with plasma supplementation during surgery or severe bleeding episodes. In addition, prothrombin complex concentrates and combination therapy with recombinant activated FVII and vitamin K supplementation may constitute alternative treatment options. The overall prognosis is good and with the availability of several effective therapeutic options, VKCFD has only a small impact on the quality of life of affected patients.</p>
url http://www.ojrd.com/content/5/1/21
work_keys_str_mv AT marianiguglielmo hereditarycombineddeficiencyofthevitaminkdependentclottingfactors
AT napolitanomariasanta hereditarycombineddeficiencyofthevitaminkdependentclottingfactors
AT lapecorellamario hereditarycombineddeficiencyofthevitaminkdependentclottingfactors
_version_ 1725320176615817216